Clinical features of 19 patients with SIL-TAL1-positive T-cell acute lymphoblastic leukemia.
10.3760/cma.j.issn.0253-2727.2023.02.008
- Author:
Li Jun WANG
1
;
Yu CHEN
1
;
Meng XIANG
1
;
Xiao Fei YANG
1
;
Su Ning CHEN
1
Author Information
1. The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Medical Research Center for Hematological Diseases, Suzhou 215006, China.
- Publication Type:Journal Article
- Keywords:
Hematopoietic stem cell transplantation;
Leukemia, T lymphocytic, acute;
Prognosis;
SIL-TAL1 fusion gene
- MeSH:
Adolescent;
Adult;
Humans;
Male;
Young Adult;
Chromosome Aberrations;
Oncogene Proteins, Fusion/genetics*;
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma;
Prognosis;
Recurrence;
Retrospective Studies;
T-Cell Acute Lymphocytic Leukemia Protein 1/genetics*;
T-Lymphocytes;
Female;
Child
- From:
Chinese Journal of Hematology
2023;44(2):132-136
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To assess the clinical characteristics and prognosis of patients with SIL-TAL1-positive T-cell acute lymphoblastic leukemia (T-ALL) . Methods: The clinical data of 19 SIL-TAL1-positive T-ALL patients admitted to the First Affiliated Hospital of Soochow University between January 2014 and February 2022 were retrospectively computed and contrasted with SIL-TAL1-negative T-ALL patients. Results: The median age of the 19 SIL-TAL1-positive T-ALL patients was 15 (7 to 41 years) , including 16 males (84.2%) . SIL-TAL1-positive T-ALL patients had younger age, higher WBC, and hemoglobin compared with SIL-TAL1-negative T-ALL patients. There was no discrepancy in gender distribution, PLT, chromosome abnormality distribution, immunophenotyping, and complete remission (CR) rate. The 3-year overall survival (OS) was 60.9% and 74.4%, respectively (HR=2.070, P=0.071) . The 3-year relapse-free survival (RFS) was 49.2% and 70.6%, respectively (HR=2.275, P=0.040) . The 3-year RFS rate of SIL-TAL1-positive T-ALL patients was considerably lower than SIL-TAL1-negative T-ALL patients. Conclusion: SIL-TAL1-positive T-ALL patients were connected to younger age, higher WBC, higher HGB, and poor outcome.
